Revlimid (lenalidomide) Letter of Medical Necessity
Revlimid (lenalidomide) requires REMS program enrollment due to teratogenicity. With generic lenalidomide now available, PAs increasingly require justification for brand selection.
FDA-Approved Indications
- ● multiple myeloma
- ● mantle cell lymphoma
- ● follicular lymphoma
- ● marginal zone lymphoma
- ● myelodysplastic syndromes (5q deletion)
Why Revlimid Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. REMS enrollment not documented
- 2. Diagnosis not confirmed
- 3. Line of therapy not specified
- 4. Generic lenalidomide preferred
What to Include in a Revlimid Letter of Medical Necessity
Document hematologic diagnosis, REMS enrollment, prior therapies, planned regimen, and clinical rationale for brand vs generic if applicable.
Key clinical evidence to cite:
- ✓ Multiple pivotal trials across indications
Relevant guidelines:
- 📖 NCCN Multiple Myeloma Guidelines
- 📖 NCCN B-cell Lymphomas
Revlimid Prior Authorization Criteria
Standard criteria across major US payers for Revlimid. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Revlimid
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Revlimid Prior Authorization FAQ
Why was my Revlimid prior authorization denied?
The most common denial reasons for Revlimid are: REMS enrollment not documented; Diagnosis not confirmed; Line of therapy not specified; Generic lenalidomide preferred.
What should a Revlimid Letter of Medical Necessity include?
Document hematologic diagnosis, REMS enrollment, prior therapies, planned regimen, and clinical rationale for brand vs generic if applicable.
Which payers cover Revlimid?
Revlimid is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part D, though formulary tier and prior authorization criteria vary.